Adaptimmune Therapeutics plc
ADAP
$0.0569
-$0.0016-2.74%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -143.64% | 1.89% | -54.88% | 61.37% | 425.03% |
| Total Depreciation and Amortization | -8.50% | -12.86% | -1.25% | -2.56% | 22.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.90% | -103.71% | 455.71% | 161.78% | 113.30% |
| Change in Net Operating Assets | 71.77% | -306.11% | -9.66% | -869.73% | -364.79% |
| Cash from Operations | -173.38% | -108.43% | -133.06% | -20.58% | 208.31% |
| Capital Expenditure | 82.23% | -1,079.41% | 73.52% | 50.52% | 65.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5,883.49% | 16,645.70% | -87.85% | -214.38% | 99.22% |
| Cash from Investing | 2,588.56% | 11,595.53% | -88.02% | -215.20% | -127.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 13,683.33% | -99.55% | -98.65% | -99.83% | -14.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -93.25% | -186.61% | -98.65% | 4,094.80% | 174,985.71% |
| Foreign Exchange rate Adjustments | -2,850.00% | 233.65% | -151.43% | 65.89% | 89.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -121.40% | -1,338.87% | -148.60% | -840.01% | 272.51% |